We Are Excited to Introduce You to the 11th Editor-in-Chief Dr. Bob Löwenberg – Blood Journals Portfolio
Blood Journals Portfolio shared on LinkedIn:
”In continued celebration of Blood’s 80th anniversary, we’re excited to introduce you to the 11th Editor-in-Chief, Dr. Bob Löwenberg.
Bob Löwenberg, MD, PhD, is a Principal Investigator and Professor of Hematology in the Department of Hematology at the Erasmus MC, where he has worked since 1990.
From 1982-1990, dr. Löwenberg was Director of Research at Daniel den Hoed Cancer Center in Rotterdam, Netherlands and from 1983-1986, he was a Visiting Professor at Free University Brussel.
From 1990-2011, he served as the Chairman of the Department of Hematology at Erasmus University Medical Center.
Dr. Löwenberg was one of the founders of European Hematology Association (EHA) and has served as President.
He has also been President of the International Society of Experimental Hematology and the International Society of Hematology and is a past Chairman of the Scientific Advisory Board.
He also founded and served as the first President of the Dutch-Belgian Cooperative Group on Hemato-Oncology in Adults.
Serving as Editor-in-Chief of Blood from 2013-2019, he was quoted in 2016 saying,
‘Blood has been a crucial and loyal partner for successive generations of hematologists.The Journal has faithfully reported the profound changes in clinical practice and biologic concepts that have revolutionized hematology during the last 70 years, and my goal – and the goal of our terrific team of colleague-editors and dedicated staff – is to continue to keep the needs of our current readership in mind.It is an honor to be the guardian of the Journal during this anniversary, and to be trusted to uphold the standards that our predecessors have established.’
Dr. Lowenberg remains a close friend of American Society of Hematology, and we’re grateful for all he’s contributed to Blood and the field of hematology overall.
Keep an eye out for our feature on the 12th EIC next week!
Source.”
Stay updated with Hemostasis Today.
-
Sep 11, 2026, 11:24Haroun Gajraj: Polidocanol or STS – Choosing the Right Sclerosant
-
Sep 11, 2026, 10:53A Patient-Centred Approach to Haemophilia B Care – EAHAD
-
Sep 11, 2026, 09:51Alfredo Lozada: Pelacarsen Lowers Lp(a), But Does It Lower CV Risk?
-
Sep 11, 2026, 09:35Yasir Khan: Travel Related Blood Clots – What Are the Chances?
-
Sep 11, 2026, 08:02Mud Alvi: Restarting Antithrombotic Therapy After Hemorrhagic Transformation of Ischemic Stroke
-
Sep 11, 2026, 08:01Chaza Alaji: Factor X From Inherited Deficiency to Acquired Deficiency in AL Amyloidosis
-
Sep 11, 2026, 08:01Mariusz Kowalewski: Risk Stratification of Surgical Ablation During Minimally Invasive Mitral Valve Surgery for AFib
-
Sep 11, 2026, 08:00Noor Gajraj: MTHFR Helps Turn Folate, Vitamin B9, Into The Form The Body Uses
-
Sep 11, 2026, 07:59Lisa Lacy: Living With Hereditary Antithrombin Deficiency and the Constant Threat of Clotting